Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.

Vaccine
Joel V ChuaMohammad M Sajadi

Abstract

A major challenge for HIV vaccine development is to raise anti-envelope antibodies capable of recognizing and neutralizing diverse strains of HIV-1. Accordingly, a full length single chain (FLSC) of gp120-CD4 chimeric vaccine construct was designed to present a highly conserved CD4-induced (CD4i) HIV-1 envelope structure that elicits cross-reactive anti-envelope humoral responses and protective immunity in animal models of HIV infection. IHV01 is the FLSC formulated in aluminum phosphate adjuvant. We enrolled 65 healthy adult volunteers in this first-in-human phase 1a randomized, double-blind, placebo-controlled study with three dose-escalating cohorts (75 µg, 150 µg, and 300 µg doses). Intramuscular injections were given on weeks 0, 4, 8, and 24. Participants were followed for an additional 24 weeks after the last immunization. The overall incidence of adverse events (AEs) was not significantly different between vaccinees and controls. The majority (89%) of vaccine-related AE were mild. The most common vaccine-related adverse event was injection site pain. There were no vaccine-related serious AE, discontinuation due to AE, intercurrent HIV infection, or significant decreases in CD4 count. By the final vaccination, all vaccine...Continue Reading

References

Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Chih-chin HuangPeter D Kwong
Feb 3, 2005·The Journal of Infectious Diseases·Neil M FlynnUNKNOWN rgp120 HIV Vaccine Study Group
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·V Raúl Gómez-RománMarjorie Robert-Guroff
May 4, 2005·The Journal of Experimental Medicine·Julie M DeckerGeorge M Shaw
Nov 17, 2006·The Journal of Infectious Diseases·Punnee PitisuttithumUNKNOWN Bangkok Vaccine Evaluation Group
Oct 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anthony DeVicoRanajit Pal
Nov 30, 2007·Current HIV Research·Anthony L DeVico
Aug 1, 2008·Nature·Jun LiuSriram Subramaniam
Nov 21, 2008·Methods in Molecular Biology·David C Montefiori
Feb 20, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yongjun GuanGeorge K Lewis
Mar 7, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ruth H FloreseMarjorie Robert-Guroff
Oct 22, 2009·The New England Journal of Medicine·Supachai Rerks-NgarmUNKNOWN MOPH-TAVEG Investigators
Apr 6, 2012·The New England Journal of Medicine·Barton F HaynesJerome H Kim
Jul 19, 2012·PLoS Pathogens·Erin E H TranSriram Subramaniam
Dec 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Yongjun GuanGeorge K Lewis
May 11, 2013·Proceedings of the National Academy of Sciences of the United States of America·Georgia D TomarasBarton F Haynes
Oct 9, 2013·The New England Journal of Medicine·Scott M HammerUNKNOWN HVTN 505 Study Team
Nov 7, 2013·Current HIV Research·Marit KramskiStephen J Kent
Mar 29, 2014·Current Opinion in HIV and AIDS·George K LewisAnthony L Devico
Feb 15, 2015·Proceedings of the National Academy of Sciences of the United States of America·Timothy R FoutsRobert C Gallo
May 20, 2016·Clinical and Vaccine Immunology : CVI·Jennifer A SchwartzTimothy R Fouts
Sep 4, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shari N GordonGenoveffa Franchini
Jan 31, 2017·Immunological Reviews·George K LewisAnthony L DeVico

❮ Previous
Next ❯

Software Mentioned

R
Tidyverse
Exact
lme4

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.